COMMUNIQUÉS West-GlobeNewswire

Osivax Announces First Participant Vaccinated in Phase 2b Trial Evaluating Broad-Spectrum Influenza A Vaccine Candidate, OVX836
16/09/2025
Phase 2b to assess efficacy, safety, and immunogenicity 2,850 participants to be enrolled across European countries Lyon, France and Liège, Belgium – September 16, 2025 – Osivax , a biopharmaceutical company developing [...]
Manchester charity recognises UK hero volunteers
16/09/2025
Human Appeal’s Purple Legacy Awards returned for the second year MANCHESTER, United Kingdom, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Manchester-based humanitarian charity, Human Appeal, announced its second awards ceremony, [...]
New Imprivata Report Finds that UK Hospitals Save More Than £522K Annually with Shared-Use Mobile Devices, but Gaps in Strategy Pose Risks
16/09/2025
The 2025 Imprivata State of Shared Mobile Devices in Healthcare Report reveals both opportunity and challenges for UK healthcare organisations to better leverage shared-use mobile devices in the delivery of patient care [...]
Cumulus Oncology Strengthens Board of Directors & Scientific Advisory Team
16/09/2025
Appoints Dr Manuel Aivado as Director and Dr Brian Jones as Scientific Advisor EDINBURGH, Scotland, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Cumulus Oncology, an oncology and inflammation focused biotech , announces the [...]
Cantoni Therapeutics secures financing to advance novel non-incretin obesity drug into IND enabling phase
16/09/2025
Brabant Development Agency (BOM) and angel investor join lead investor Libertatis Ergo Holding (LEH) in providing funding, with additional financial support from Brabant Startup Fund (BSF) Cantoni awarded validatioNN [...]
Transforming Global Healthcare: Inteleos Debuts Sonography Certification at Eight New UAE Testing Centers
16/09/2025
New Locations Unlock Regional Access to Certification, Expand Opportunity for Professionals to Obtain ISO-Certified Credentials Healthcare credentialing leader advances equity and excellence in diagnostic ultrasound for [...]
Basilea receives USD 25 million funding under BARDA agreement to continue to advance novel antifungals fosmanogepix and BAL2062
16/09/2025
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, September 16, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of [...]

Pages